Regression of renal vascular fibrosis by endothelin receptor antagonism.
In previous studies, we have observed that endothelin participates in the progression of renal vascular and glomerular fibrosis during hypertension by activating collagen I gene synthesis. The present study investigated whether administration of endothelin receptor antagonists leads to the regression of renal sclerotic lesions. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-alpha2 chain promoter. Hypertension was induced by long-term inhibition of nitric oxide synthesis by N(G)-nitro-L-arginine methyl ester (L-NAME); systolic pressure gradually increased, reaching a plateau of 165 mm Hg after 10 weeks of hypertensive treatment. At the same time, collagen I gene expression was increased 2- and 5-fold compared with control animals in afferent arterioles and glomeruli, respectively (P<0.01). This increase was accompanied by the appearance of sclerotic lesions within the renal vasculature. When renal vascular lesions had been established (20 weeks of L-NAME), animals were divided into 2 subgroups: the one continued to receive L-NAME, whereas in the other, bosentan, a dual endothelin antagonist, was coadministered with L-NAME for an additional period of 10 weeks. Bosentan coadministration did not alter the increased systolic pressure at 30 weeks; in contrast, collagen I gene activity returned almost to control levels in renal vessels and glomeruli. In this subgroup of animals, renal vascular lesions (collagen and/or extracellular matrix deposition) and mortality rates were substantially reduced compared with untreated mice. These data indicate that endothelin participates in the mechanism(s) of renal vascular fibrosis by activating collagen I gene. Treatment with an endothelin antagonist normalizes expression of collagen I gene and leads to the regression of renal vascular fibrosis and to the improvement of survival, thus providing a complementary curative approach against renal fibrotic complications associated with hypertension.
Boffa
J J
JJ
INSERM U.489, Hôpital Tenon, Paris, France.
Tharaux
P L
PL
Dussaule
J C
JC
Chatziantoniou
C
C
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure; D000077300:Bosentan; D003094:Collagen / Q000096:biosynthesis / Q000235:genetics; D024042:Collagen Type I; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000037:antagonists & inhibitors* / Q000502:physiology; D005355:Fibrosis; D005786:Gene Expression Regulation; D006978:Hypertension, Renovascular / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D007678:Kidney Glomerulus / Q000473:pathology; D008156:Luciferases / Q000235:genetics; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D019331:NG-Nitroarginine Methyl Ester; D010477:Perfusion; D012077:Renal Artery / Q000378:metabolism / Q000473:pathology*; D013194:Staining and Labeling; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
D000959:Antihypertensive Agents; D024042:Collagen Type I; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D013449:Sulfonamides; D003094:Collagen; D008156:Luciferases; D000077300:Bosentan; D019331:NG-Nitroarginine Methyl Ester